Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Impact of Neoadjuvant Chemotherapy With or Without Zometa on Occult Micrometastases and Bone Density in Women With Locally Advanced Breast Cancer
Brief Summary: This study is designed to evaluate the impact of Zometa on clearance of bone marrow micrometastases; the protective effect on chemotherapy-induced loss of bone mineral density; and quality of life in women undergoing treatment for locally advanced breast cancer.


Options:
A: Arm Label: Upfront Zoledronic Acid; Type: EXPERIMENTAL; Interventions: Drug: Zoledronic acid, Drug: Letrozole | Arm Label: Delayed Zoledronic Acid; Type: EXPERIMENTAL; Interventions: Drug: Zoledronic acid, Drug: Letrozole | Intervention Type: DRUG; Name: Zoledronic acid; Assigned to Arm(s): Delayed Zoledronic Acid, Upfront Zoledronic Acid | Intervention Type: DRUG; Name: Letrozole; Assigned to Arm(s): Delayed Zoledronic Acid, Upfront Zoledronic Acid
B: Arm Label: Zometa; Type: EXPERIMENTAL; Interventions: Drug: Zometa, Drug: Epirubicin, Drug: Docetaxel, Drug: Trastuzumab, Radiation: External beam radiation, Procedure: Modified radical mastectomy or breast conserving surgery with axillary lymph node dissection | Arm Label: No Zometa; Type: ACTIVE_COMPARATOR; Interventions: Drug: Epirubicin, Drug: Docetaxel, Drug: Trastuzumab, Radiation: External beam radiation, Procedure: Modified radical mastectomy or breast conserving surgery with axillary lymph node dissection | Intervention Type: DRUG; Name: Zometa; Assigned to Arm(s): Zometa | Intervention Type: DRUG; Name: Epirubicin; Assigned to Arm(s): No Zometa, Zometa | Intervention Type: DRUG; Name: Docetaxel; Assigned to Arm(s): No Zometa, Zometa | Intervention Type: DRUG; Name: Trastuzumab; Assigned to Arm(s): No Zometa, Zometa | Intervention Type: RADIATION; Name: External beam radiation; Assigned to Arm(s): No Zometa, Zometa | Intervention Type: PROCEDURE; Name: Modified radical mastectomy or breast conserving surgery with axillary lymph node dissection; Assigned to Arm(s): No Zometa, Zometa
C: Arm Label: A; Type: PLACEBO_COMPARATOR; Interventions: Drug: risedronate (including placebo) | Intervention Type: DRUG; Name: risedronate (including placebo); Assigned to Arm(s): A
D: Arm Label: Denosumab; Type: EXPERIMENTAL; Interventions: Biological: Denosumab, Drug: Non-steroidal aromatase inhibitor therapy | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo, Drug: Non-steroidal aromatase inhibitor therapy | Arm Label: SubStudy: Zoledronic Acid; Type: EXPERIMENTAL; Interventions: Drug: Zoledronic Acid | Arm Label: Substudy: Standard of Care; Type: OTHER; Interventions: Other: Standard of Care | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo | Intervention Type: BIOLOGICAL; Name: Denosumab; Assigned to Arm(s): Denosumab | Intervention Type: DRUG; Name: Non-steroidal aromatase inhibitor therapy; Assigned to Arm(s): Denosumab, Placebo | Intervention Type: DRUG; Name: Zoledronic Acid; Assigned to Arm(s): SubStudy: Zoledronic Acid | Intervention Type: OTHER; Name: Standard of Care; Assigned to Arm(s): Substudy: Standard of Care

Answer: B